Dataset from A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00005141
下载链接
链接失效反馈官方服务：
资源简介：
The primary purpose of this study is to obtain long-term safety data with CZP in patients with Rheumatoid Arthritis (RA). Additional objectives are to assess the dose and type of Arthritis medication(s) utilized by patients, and to assess the long-term impact of CZP on physical function. Treatment will continue up to approval of a marketing application for this product.
创建时间：
2025-02-22
